At the TMB & Neoantigen Congress, UK, you can explore discoveries and developments in novel immuno-targets, predictive biomarkers for tumor, and personalized medicine.
One of the key advantages of immuno-oncology is the potential to offer targeted personalized care for patients. However, challenges remain in matching patients to the therapies that offer the greatest chance of success, limiting efficacy depending on individual circumstances and increasing costs. Thus technologies that can assist in guiding therapies are vital – a role filled by predicted biomarker and neoantigen research.
This conference will explore the latest research on the tumor mutation burden and its potential for demonstrating the viability of immunotherapeutic treatment, as well as the development of other predictive biomarkers. A dedicated session will also examine the growing potential of neoantigens as novel targets for precision medicine.
A ticket to this congress can be used to access four co-located meetings:
- Liquid Biopsies Congress
- Flow Cytometry Congress
- Adoptive Cell Transfer Congress
- Novel Antibody Therapeutics Congress
Date: 10th-11th October 2019 | 9.00 am – 5.00 pm
Venue: London Heathrow Marriott Hotel, Bath Road Heathrow Airport, Hayes UB3 5AN
For any inquiries, please contact:
Jane Williams | firstname.lastname@example.org | (0)1865 849841